FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023843612> ?p ?o ?g. }

• W2023843612 endingPage "253" @default.
• W2023843612 startingPage "240" @default.
• W2023843612 abstract "Tumor Necrosis Factor-alpha Related Apoptosis Inducing Ligand (TRAIL) and agonistic antibodies to death receptors (DR) 4 and 5 have attracted significant attention in recent years due to their ability to selectively induce apoptosis in malignant cells while demonstrating little cytotoxicity in normal cells. Although these candidates are promising in cancer therapy, a number of tumor cells are resistant to TRAIL-mediated apoptosis. We describe the use of a cationic amphipathic lytic peptide, KLA (single letter sequence HHHHHKLAKLAKKLAKLAKC), for the chemosensitization of TRAIL-resistant LNCaP and PC3-PSMA human prostate cancer cells to DR agonistic antibodies. 'Single-agent' treatment with DR agonistic antibodies did not result in loss of viability of these cells confirming the resistance of these cells. However, the combination treatment of KLA followed by DR agonists resulted in greater cell death compared to the individual treatments acting alone, indicating synergistic action between the two components of the combination treatment. The combination of lytic peptide and DR agonists resulted in a significant increase in activated caspase-3 cleavage and cytochrome-C protein levels in cells, indicating a role for the caspase-mediated apoptotic pathway. In addition, KLA treatment also resulted in increased localization of DR5 and lipid rafts in LNCaP cells. Our results demonstrate, for the first time, that lytic peptides can be employed for sensitizing TRAIL-resistant prostate cancer cells to DR-mediated apoptosis resulting in novel combination treatments for the ablation of advanced cancer cells." @default.
• W2023843612 created "2016-06-24" @default.
• W2023843612 creator A5003331485 @default.
• W2023843612 creator A5031797084 @default.
• W2023843612 creator A5055658784 @default.
• W2023843612 creator A5083946093 @default.
• W2023843612 creator A5087278493 @default.
• W2023843612 creator A5087311756 @default.
• W2023843612 date "2010-07-01" @default.
• W2023843612 modified "2023-10-16" @default.
• W2023843612 title "Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists" @default.
• W2023843612 cites W1550144060 @default.
• W2023843612 cites W1587050401 @default.
• W2023843612 cites W1920968130 @default.
• W2023843612 cites W1966334119 @default.
• W2023843612 cites W1967799012 @default.
• W2023843612 cites W1967992429 @default.
• W2023843612 cites W1969327970 @default.
• W2023843612 cites W1972862393 @default.
• W2023843612 cites W1974381618 @default.
• W2023843612 cites W1978458547 @default.
• W2023843612 cites W1986053719 @default.
• W2023843612 cites W1986705787 @default.
• W2023843612 cites W1991440322 @default.
• W2023843612 cites W1992410150 @default.
• W2023843612 cites W1997888702 @default.
• W2023843612 cites W1998650748 @default.
• W2023843612 cites W1999134519 @default.
• W2023843612 cites W2000638372 @default.
• W2023843612 cites W2001327683 @default.
• W2023843612 cites W2004952453 @default.
• W2023843612 cites W2021501434 @default.
• W2023843612 cites W2026057304 @default.
• W2023843612 cites W2030727312 @default.
• W2023843612 cites W2031213053 @default.
• W2023843612 cites W2043966745 @default.
• W2023843612 cites W2049474922 @default.
• W2023843612 cites W2051808238 @default.
• W2023843612 cites W2052607700 @default.
• W2023843612 cites W2052703537 @default.
• W2023843612 cites W2053058618 @default.
• W2023843612 cites W2055580039 @default.
• W2023843612 cites W2090443758 @default.
• W2023843612 cites W2092566647 @default.
• W2023843612 cites W2094570524 @default.
• W2023843612 cites W2102630679 @default.
• W2023843612 cites W2103097932 @default.
• W2023843612 cites W2111437705 @default.
• W2023843612 cites W2119326933 @default.
• W2023843612 cites W2124153229 @default.
• W2023843612 cites W2156373113 @default.
• W2023843612 cites W2158482458 @default.
• W2023843612 cites W2320692584 @default.
• W2023843612 cites W2320870975 @default.
• W2023843612 cites W2330709458 @default.
• W2023843612 cites W2334948925 @default.
• W2023843612 cites W4232547688 @default.
• W2023843612 doi "https://doi.org/10.1016/j.canlet.2010.01.012" @default.
• W2023843612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20347216" @default.
• W2023843612 hasPublicationYear "2010" @default.
• W2023843612 type Work @default.
• W2023843612 sameAs 2023843612 @default.
• W2023843612 citedByCount "13" @default.
• W2023843612 countsByYear W20238436122012 @default.
• W2023843612 countsByYear W20238436122013 @default.
• W2023843612 countsByYear W20238436122014 @default.
• W2023843612 countsByYear W20238436122017 @default.
• W2023843612 countsByYear W20238436122019 @default.
• W2023843612 countsByYear W20238436122020 @default.
• W2023843612 countsByYear W20238436122021 @default.
• W2023843612 crossrefType "journal-article" @default.
• W2023843612 hasAuthorship W2023843612A5003331485 @default.
• W2023843612 hasAuthorship W2023843612A5031797084 @default.
• W2023843612 hasAuthorship W2023843612A5055658784 @default.
• W2023843612 hasAuthorship W2023843612A5083946093 @default.
• W2023843612 hasAuthorship W2023843612A5087278493 @default.
• W2023843612 hasAuthorship W2023843612A5087311756 @default.
• W2023843612 hasConcept C109316439 @default.
• W2023843612 hasConcept C121608353 @default.
• W2023843612 hasConcept C126322002 @default.
• W2023843612 hasConcept C170493617 @default.
• W2023843612 hasConcept C182615771 @default.
• W2023843612 hasConcept C185592680 @default.
• W2023843612 hasConcept C190283241 @default.
• W2023843612 hasConcept C202751555 @default.
• W2023843612 hasConcept C203014093 @default.
• W2023843612 hasConcept C2522874641 @default.
• W2023843612 hasConcept C2779723316 @default.
• W2023843612 hasConcept C2780192828 @default.
• W2023843612 hasConcept C31573885 @default.
• W2023843612 hasConcept C502942594 @default.
• W2023843612 hasConcept C55493867 @default.
• W2023843612 hasConcept C71924100 @default.
• W2023843612 hasConcept C86803240 @default.
• W2023843612 hasConcept C96232424 @default.
• W2023843612 hasConceptScore W2023843612C109316439 @default.
• W2023843612 hasConceptScore W2023843612C121608353 @default.
• W2023843612 hasConceptScore W2023843612C126322002 @default.

• next